The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Open accessAbstract
Background: The increasing problem of multidrug-resistant Gram-negative bacteria causing severe infections and the shortage of new antibiotics to combat them has led to the re-evaluation of polymyxins. These antibiotics were discovered from different species of Bacillus polymyxa in 1947; only two of them, polymyxin B and E (colistin), have been used in clinical practice. Their effectiveness in the treatment of infections due to susceptible Gram-negative bacteria, including Pseudomonas aeruginosa and Acinetobacter baumannii, has not been generally questioned. However, their use was abandoned, except in patients with cystic fibrosis, because of concerns related to toxicity. Methods: We reviewed old and recent evidence regarding polymyxin-induced toxicity by searching Pubmed (from 1950 until May 2005). Results: It was reported in the old literature that the use of polymyxins was associated with considerable toxicity, mainly nephrotoxicity and neurotoxicity, including neuromuscular blockade. However, recent studies showed that the incidence of nephrotoxicity is less common and severe compared to the old studies. In addition, neurotoxic effects of polymyxins are usually mild and resolve after prompt discontinuation of the antibiotics. Furthermore, cases of neuromuscular blockade and apnea have not been reported in the recent literature. Conclusion: New evidence shows that polymyxins have less toxicity than previously reported. The avoidance of concurrent administration of nephrotoxic and/or neurotoxic drugs, careful dosing, as well as more meticulous management of fluid and electrolyte abnormalities and use of critical care services may be some of the reasons for the discrepancy between data reported in the old and recent literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Self-citationPolymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
Frederiksen, B., Koch, C., & Høiby, N. (1997) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o · Cited by 473
Garnacho‐Montero, J., Ortiz‐Leyba, C., Jimenez‐Jimenez, F. J., Barrero‐Almodovar, A. E., Garcia‐Garmendia, J. L., Bernabeu‐WittelI, M., Gallego‐Lara, S. L., & Madrazo‐Osuna, J. (2003) · Clinical Infectious Diseases · doi:10.1086/374337 · Cited by 470
Jensen, T., Pedersen, S. S., Garne, S., Heilmann, C., Høiby, N., & Koch, C. (1987) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/19.6.831 · Cited by 314
Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S., & Falagas, M. E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01043.x · Cited by 292
Self-citationMarkou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Linden, P. K., Kusne, S., Coley, K., Fontes, P., Kramer, D. J., & Paterson, D. (2003) · Clinical Infectious Diseases · doi:10.1086/379611 · Cited by 252
Toxicity after prolonged (more than four weeks) administration of intravenous colistin
Falagas, M. E., Rizos, M., Bliziotis, I. A., Rellos, K., Kasiakou, S. K., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-1 · Cited by 242
Self-citation
Cited by
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Pseudomonas aeruginosa : new insights into pathogenesis and host defenses
Gellatly, S. L., & Hancock, R. E. W. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12033 · Cited by 1,295
Antimicrobial Resistance: a One Health Perspective
McEwen, S. A., & Collignon, P. J. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.arba-0009-2017 · Cited by 1,199
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections
Driscoll, J. A., Brody, S. L., & Kollef, M. H. (2007) · Drugs · doi:10.2165/00003495-200767030-00003 · Cited by 884
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Munoz-Price, L. S., & Weinstein, R. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra070741 · Cited by 772
Mechanisms and consequences of bacterial resistance to antimicrobial peptides
Andersson, D. I., Hughes, D., & Kubicek-Sutherland, J. Z. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.04.002 · Cited by 715
Ayoub Moubareck, C., & Hammoudi Halat, D. (2020) · Antibiotics · doi:10.3390/antibiotics9030119 · Cited by 627
Contribution of bacterial outer membrane vesicles to innate bacterial defense
Manning, A. J., & Kuehn, M. J. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-258 · Cited by 622
Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design
Li, J., Koh, J.-J., Liu, S., Lakshminarayanan, R., Verma, C. S., & Beuerman, R. W. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00073 · Cited by 611
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Antimicrobial resistance: One Health approach
Velazquez-Meza, M. E., Galarde-López, M., Carrillo-Quiróz, B., & Alpuche-Aranda, C. M. (2022) · Veterinary World · doi:10.14202/vetworld.2022.743-749 · Cited by 571
Cai, Y., Chai, D., Wang, R., Liang, B., & Bai, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks084 · Cited by 557
Gan, B. H., Gaynord, J., Rowe, S. M., Deingruber, T., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00729c · Cited by 511
Pamp, S. J., Gjermansen, M., Johansen, H. K., & Tolker‐Nielsen, T. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06152.x · Cited by 486
Lipopeptides from Bacillus and Paenibacillus spp.: A Gold Mine of Antibiotic Candidates
Cochrane, S. A., & Vederas, J. C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21321 · Cited by 474
Polymyxin: Alternative Mechanisms of Action and Resistance
Trimble, M. J., Mlynárčik, P., Kolář, M., & Hancock, R. E. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025288 · Cited by 454
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Karageorgopoulos, D. E., & Falagas, M. E. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70279-2 · Cited by 446
Self-citationResurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1279 · Cited by 444
Nation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
Dijksteel, G. S., Ulrich, M. M. W., Middelkoop, E., & Boekema, B. K. H. L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.616979 · Cited by 428
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 421
Neurotoxic effects associated with antibiotic use: management considerations
Grill, M. F., & Maganti, R. K. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03991.x · Cited by 410
One Health—Its Importance in Helping to Better Control Antimicrobial Resistance
Collignon, P. J., & McEwen, S. A. (2019) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed4010022 · Cited by 407
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
Hirsch, E. B., & Tam, V. H. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.49 · Cited by 406
Scott, P., Deye, G., Srinivasan, A., Murray, C., Moran, K., Hulten, E., Fishbain, J., Craft, D., Riddell, S., Lindler, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/518170 · Cited by 393
Antibiotic resistance breakers: current approaches and future directions
Laws, M., Shaaban, A., & Rahman, K. M. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz014 · Cited by 356
Nation, R. L., Li, J., Cars, O., Couet, W., Dudley, M. N., Kaye, K. S., Mouton, J. W., Paterson, D. L., Tam, V. H., Theuretzbacher, U., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70850-3 · Cited by 354
Zilberberg, M. D., Shorr, A. F., Micek, S. T., Vazquez-Guillamet, C., & Kollef, M. H. (2014) · Critical Care · doi:10.1186/preaccept-6556009101270526 · Cited by 340
Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia
Hsu, L.-Y., Apisarnthanarak, A., Khan, E., Suwantarat, N., Ghafur, A., & Tambyah, P. A. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-16 · Cited by 339
Pogue, J. M., Lee, J., Marchaim, D., Yee, V., Zhao, J. J., Chopra, T., Lephart, P., & Kaye, K. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir611 · Cited by 327
The enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E. A., Ferguson, E. L., & Thomas, D. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 312
A review on colistin nephrotoxicity
Ordooei Javan, A., Shokouhi, S., & Sahraei, Z. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1865-4 · Cited by 287
Antimicrobial peptides towards clinical application: Delivery and formulation
Wang, C., Hong, T., Cui, P., Wang, J., & Xia, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.028 · Cited by 281
Renal and neurological side effects of colistin in critically ill patients
Spapen, H., Jacobs, R., Van Gorp, V., Troubleyn, J., & Honoré, P. M. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-14 · Cited by 281
A new strategy to fight antimicrobial resistance: the revival of old antibiotics
Cassir, N., Rolain, J.-M., & Brouqui, P. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00551 · Cited by 280
Pharmacology behind Common Drug Nephrotoxicities
Perazella, M. A. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00150118 · Cited by 270
Kanj, S. S., & Kanafani, Z. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0674 · Cited by 269
Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation
Jiang, Y., Chen, Y., Song, Z., Tan, Z., & Cheng, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.016 · Cited by 267
Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria
Gogry, F. A., Siddiqui, M. T., Sultan, I., & Haq, Q. M. R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.677720 · Cited by 265
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections
Wagner, S., Sommer, R., Hinsberger, S., Lu, C., Hartmann, R. W., Empting, M., & Titz, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01698 · Cited by 258
Lu, J., Xu, H., Xia, J., Ma, J., Xu, J., Li, Y., & Feng, J. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.563030 · Cited by 257
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Kett, D. H., Cano, E., Quartin, A. A., Mangino, J. E., Zervos, M. J., Peyrani, P., Cely, C. M., Ford, K. D., Scerpella, E. G., & Ramirez, J. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70314-5 · Cited by 235
Functional Evaluation and Nephrotoxicity Assessment of Human Renal Proximal Tubule Cells on a Chip
Jing, B., Yan, L., Li, J., Luo, P., Ai, X., & Tu, P. (2022) · Biosensors · doi:10.3390/bios12090718 · Cited by 21
Metadata
- Authors
- Falagas, M. E., & Kasiakou, S. K.
- Venue
- Critical Care
- Published
- 2006-02-13
- Volume
- 10
- Issue
- 1
- Pages
- R27-R27
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W1602597014
- Cited by
- 828
- References
- 26
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.